Episode 437: Precision Oncology: What We've Learned and What's Ahead
From The ONS Podcast · · 29 min
This plays from the publisher's own server. We do not host a copy.
Description
"Biomarker testing isn't just about generating more information. It's about answering very practical questions for our patients. Can we identify disease earlier? Can we understand whether treatment is working? Are we able to identify why a cancer has become resistant? Ultimately, I think that's where precision oncology becomes very meaningful. It's not about the molecular report sitting in the chart. It's about taking that information and using it to make the best possible decision for our individual patients," ONS member Erica Bello Rodriguez, MSN, AGNP, NP-C, AOCNP®, oncology nurse practitioner and supervisor of advanced practice providers at Northwell Health Cancer Institute in Westchester, NY, told Katie Hubbard, MSN, RN, OCN®, NPD-BC, oncology clinical specialist at ONS, during a conversation about precision oncology.
This podcast episode was produced by ONS and is sponsored by AstraZeneca. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.
Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod
Licensed under Creative Commons by Attribution 3.0
Episode Notes - This episode is not eligible for NCPD contact hours.
- ONS Podcast™ episodes: - Episode 406: Drug Resistance Biomarkers and Their Impact on Cancer Treatment Choices
- Episode 238: Cancer Genomics for Every Oncology Nurse
- Episode 226: Patient Education for Next-Generation Sequencing to Guide Cancer Therapy
- Episode 169: How Biomarker Testing Drives the Use of Targeted Therapies
- ONS Voice articles: - An Oncology Nurse's Guide to Tumor-Agnostic Therapies
- Gene Alterations in Circulating Tumor DNA Can Help Guide Treatment Decisions in Patients With Advanced Breast Cancer
- Genetic Counselors Help Patients and Oncology Nurses Predict Current and Future Cancer Diagnoses
- Germline and Somatic Variants: What Is the Difference?
- Learn How to Read a Germline Genomic Testing Report
- Learn How to Read a Somatic Biomarker Testing Report
- Oncology Nurses' Role in Translating Biomarker Testing Results
- Pharmacogenomics Testing Helps to Ensure That Effective Therapy Is Safe Therapy
- The Oncology Nurse's Role in Identifying Patients for Cancer Genetics Counseling
- What Is a Liquid Biopsy?
- ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses
- Clinical Journal of Oncology Nursing articles: - Pharmacogenomic Germline Testing: Applications in Oncology Nursing
- Oncology Nurse Practitioners in Genetics: Examining Scope of Practice and Competence
- Shifting to a Biomarker Paradigm Across Cancer Care
- Using a Genomics Taxonomy: Facilitating Patient Care Safety and Quality in the Era of Precision Oncology
- ONS Huddle Cards: - Genomic Biomarkers
- Genomic Testing Methods
- Pharmacogenomics
- Referring for Germline Biomarker Testing
- ONS Biomarker Guides (https://www.ons.org/clinical-tools/biomarkers)
- ONS Genomics and Precision Oncology Learning Library
- ONS Genomics Taxonomy (https://www.ons.org/genomics-taxonomy)
- American Cancer Society: Precision or Personalized Medicine
- American Society of Clinical Oncology Publications: JCO Precision Oncology
- National Cancer Institute: Cancer Genomics Research
To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/).
To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.
To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.
Highlights From This Episode "Some of the most important developments since 2020 have really been broader than any single variant or drug. We've seen precision oncology evolve from simply identifying a genomic alteration to developing a much more comprehensive understanding of what is driving an individual's cancer and how we can act on that information.…